Although meaningful clinical studies on the efficacy and safety of MAGL inhibitors in cancer treatment are still pending, the preclinical data presented here give rise to hope that such a strategy could significantly enrich pharmacotherapies for tumor diseases. This evidence concerns the gene MGLL and neoplasm.